Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy.

Ariëns, Lieneke F M; Bakker, Daphne S; van der Schaft, Jorien; Garritsen, Floor M; Thijs, Judith L; de Bruin-Weller, Marjolein S

Ariëns, Lieneke F M; Bakker, Daphne S; van der Schaft, Jorien; Garritsen, Floor M; Thijs, Judith L; de Bruin-Weller, Marjolein S.

Afiliação

Ariëns LFM; Department of Dermatology and Allergology, University Medical Center Utrecht, Room G02.124, 3508 GA Utrecht, The Netherlands.
Bakker DS; Department of Dermatology and Allergology, University Medical Center Utrecht, The Netherlands.
van der Schaft J; Department of Dermatology and Allergology, University Medical Center Utrecht, The Netherlands.
Garritsen FM; Department of Dermatology and Allergology, University Medical Center Utrecht, The Netherlands.
Thijs JL; Department of Dermatology and Allergology, University Medical Center Utrecht, The Netherlands.
de Bruin-Weller MS; Department of Dermatology and Allergology, University Medical Center Utrecht, The Netherlands.

Ther Adv Chronic Dis ; 9(9): 159-170, 2018 Sep.

Article em En | MEDLINE | ID: mdl-30181845

Palavras-chave

atopic dermatitis; biologics; dupilumab; interleukin-13; interleukin-4; systemic treatment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Risk_factors_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google